Business Wire

Zynga Launches First-of-its-Kind Game of Thrones® Slots Casino

Del

Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that Game of Thrones Slots Casino has launched globally on the App Store and Google Play, with versions for Facebook and the Amazon Appstore coming soon. A new entry to Zynga’s social casino portfolio, the game transports players to the realm of Westeros for an authentic, social slots experience inspired by the acclaimed Game of Thrones television series from HBO®.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190530005142/en/

Game of Thrones Slots Casino from Zynga Inc. (Graphic: Business Wire)

Game of Thrones Slots Casino from Zynga Inc. (Graphic: Business Wire)

In Game of Thrones Slots Casino , players are immersed in the epic drama, arresting dialogue, iconic characters and driving musical themes of the series. From cliffhanger moments across the Seven Kingdoms, to sweeping landscapes and locations like The Wall, the best-in-class slots gameplay is infused with the fire and ice atmosphere of Westeros and its most illustrious inhabitants, including Cersei, Jaime, and Tyrion Lannister and House Stark members, Sansa, Arya, and Jon Snow.

“As longtime fans of the series, Zynga is honored to contribute to the Game of Thrones universe, and honor-bound to provide players with an experience that reflects the scale, scope, intensity, and community of the series,” said Bernard Kim, President of Publishing at Zynga. “The visual and audio design of the game truly evokes marquee moments from the series, and with our House-themed social features, players can band together to chase the throne themselves. Westeros lives on!”

Exciting social features and in-game chat in Game of Thrones Slots Casino allow players to band together to seek the seat of power and all of its rewards. By joining or forming their own House, players work with their brethren to rally through an interactive map of the Seven Kingdoms. In the weekly ‘For the Throne’ challenge, Houses are challenged to conquer each territory in turn, in a play to rule them all. The player from the victorious House that stays on top until the end of the challenge gains the right to sit atop the Iron Throne – until a new challenger claims the crown.

Game Features:

  • Authentic Game of Thrones atmosphere. Slots casino gameplay is steeped with the sounds, characters, environments and ethos of Westeros, including unforgettable dialogue such as “Winter is coming.”
  • Best-in-class slots features. Spin on exciting, Game of Thrones-themed machines, featuring real-word mechanics like Progressive Jackpots, Bursting Wilds and more.
  • Join a House and reap the rewards. Gain advantages and rewards by joining or forming a House with other players, collecting coins for every housemate’s win.
  • Strategize, scheme, align. Connect and conspire with friends via the in-game chat at any time, even when spinning the slots.
  • Collect iconic cards. Spin to earn and level up cards featuring characters from the series, from the adventurous Arya Stark, to Jon Snow’s beloved companion wolf, Ghost. Collect all of the cards to earn a massive in-game reward.

Game of Thrones Slots Casino is now available for free download on the App Store for iPhone and iPad and Google Play for Android devices. Visit www.gameofthronesslotscasino.com for more information and follow Game of Thrones Slots Casino on Instagram and Facebook.

About Zynga Inc.

Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.

About HBO Licensing & Retail

HBO Licensing & Retail, a division of Home Box Office, Inc., partners with best-in-class licensees around the world to give HBO's global audience new and exciting ways to engage with their favorite shows. The division leverages iconic, award-winning HBO programs such as Game of Thrones, VEEP, Sex and the City, Silicon Valley, Insecure, The Sopranos, Big Little Lies, True Blood and more to create officially licensed consumer products, innovative merchandise programs, retail activations and live immersive experiences. HBO Licensing & Retail works across a broad range of product categories, including collectibles, apparel, publishing, live branded experiences, digital gaming, fashion and beauty collaborations, luxury accessories, and beyond. Officially licensed HBO merchandise can be purchased in retail stores around the world and online in the US at http://store.hbo.com.

Contact information

Dana Whitney
dwhitney@zynga.com | (415) 359-7006

Or

Kjell Vistad | Gilberto Williams-Gamboa
ONE PR Studio (for Zynga in the US) / zynga@oneprstudio.com / (510) 893-3271

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 16:00:00 CESTPressemelding

Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo

MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 15:58:00 CESTPressemelding

The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha

EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 15:32:00 CESTPressemelding

EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,

Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 15:00:00 CESTPressemelding

Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc

Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 14:40:00 CESTPressemelding

Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 13:15:00 CESTPressemelding

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava